Details

Autor(en) / Beteiligte

• Nakamichi, Shinji
• Horinouchi, Hidehito
• Asao, Tetsuhiko
• Goto, Yasushi
• Kanda, Shintaro
• Fujiwara, Yutaka
• Nokihara, Hiroshi
• Yamamoto, Noboru
• Ito, Yoshinori
• Watanabe, Shunichi
• Ohe, Yuichiro

Titel

Comparison of radiotherapy and chemoradiotherapy for locoregional recurrence of non-small cell lung cancer developing after surgery

Ist Teil von

• Clinical lung cancer, 2017-11, Vol.18 (6), p.e441-e448

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2017

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• [Abstract] BACKGROUND The optimal treatment strategy for locoregional recurrences developing after surgical resection in patients with non-small cell lung cancer (NSCLC) is yet to be clearly established. PATIENTS AND METHODS To investigate the efficacy and safety of radiotherapy (RT) and chemoradiotherapy (CRT), we reviewed the consecutive data of NSCLC patients with postoperative locoregional recurrences treated at the National Cancer Center Hospital between January 2000 and April 2010. RESULTS We reviewed the data of 74 patients (including 56 who received RT alone and 18 who received CRT) according to our study criteria. The median age was lower and the N factor at the recurrence site was higher in the CRT group as compared to the RT group. Most patients received 60 Gy/30 Fr RT in both groups. The 2-year PFS rate, median PFS and OS (95% CI) were 44.4%, 19.0 months (0-41.9) and 79.6 months (8.2-151.0), respectively, in the CRT group, although those were 25.0%, 10.6 months (8.7-12.9) and 33.1 months (17.9-48.3), respectively, in the RT group. The AE profile was acceptable, with no treatment-related death in either group. Multivariate analysis identified CRT as being significantly associated with a longer PFS and OS. CONCLUSION CRT tended to yield better results than RT in terms of the survival outcomes, with acceptable safety profiles of both. We consider that a randomized study comparing RT and CRT is warranted to identify the optimal treatment strategy for NSCLC patients with postoperative locoregional recurrences.